Pepscan expands capacity at multiple gram scales to keep delivering optimal flexibility for its (GMP) customers

Pepscan’s technicians recently installed and qualified a new fully automated two-liter peptide synthesizer enabling production of 10–30 gram batches. This new piece of equipment ensures Pepscan can keep providing its clients optimal flexibility when synthesizing peptides for their clinical or research purposes; it also allows Pepscan to meet the rapidly increasing demand from clients who need peptides in  an upscaling trajectory for their clinical trials.

“In the past our peptide production capacity has at times bottlenecked, preventing us from delivering to all our customers with the desired timelines – in some cases several months for GMP batches. We needed to expand our capacity to ensure we can be flexible enough to deliver batches based on our customers’ timelines – so they can successfully run their trials,” says Evert van Dijk, CCO.

Pepscan has founded its GMP offering on its 25 years of peptide expertise. The lean processes and structures that are in place in its Dutch facility meet pharmaceutical industry standards and give Pepscan more agility in meeting its clients’ needs.

“We employ some of the industry’s finest chemists capable of applying their expertise in the fields of peptide synthesis, scaling up and analysis. I’m very pleased that this new synthesizer is now added to our toolbox, which safeguards the flexibility needed to support our customers the best way possible,” says Zoran Medic, Business development manager Biopharma.

Want to learn more about how Pepscan could contribute to making your clinical trial a success story? Contact our specialist:

Zoran Medić – Business Development Manager Biopharma